These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 36999423)

  • 41. Computational repurposing approach for targeting the critical spike mutations in B.1.617.2 (delta), AY.1 (delta plus) and C.37 (lambda) SARS-CoV-2 variants using exhaustive structure-based virtual screening, molecular dynamic simulations and MM-PBSA methods.
    Ebrahimi M; Karami L; Alijanianzadeh M
    Comput Biol Med; 2022 Aug; 147():105709. PubMed ID: 35728285
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In silico discovery of novel inhibitors from Northern African natural products database against main protease (Mpro) of SARS-CoV-2.
    Byadi S; Oblak D; Kassmi Y; Sadik K; Hachim ME; Podlipnik Č; Aboulmouhajir A
    J Biomol Struct Dyn; 2023 Apr; 41(7):2900-2910. PubMed ID: 35168469
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.
    Khare P; Sahu U; Pandey SC; Samant M
    Virus Res; 2020 Dec; 290():198169. PubMed ID: 32979476
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Protease Inhibitory Effect of Natural Polyphenolic Compounds on SARS-CoV-2: An In Silico Study.
    Singh R; Gautam A; Chandel S; Ghosh A; Dey D; Roy S; Ravichandiran V; Ghosh D
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33050360
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The New Coronavirus (SARS-CoV-2): A Comprehensive Review on Immunity and the Application of Bioinformatics and Molecular Modeling to the Discovery of Potential Anti-SARS-CoV-2 Agents.
    Villas-Boas GR; Rescia VC; Paes MM; Lavorato SN; Magalhães-Filho MF; Cunha MS; Simões RDC; Lacerda RB; Freitas-Júnior RS; Ramos BHDS; Mapeli AM; Henriques MDST; Freitas WR; Lopes LAF; Oliveira LGR; Silva JGD; Silva-Filho SE; Silveira APSD; Leão KV; Matos MMS; Fernandes JS; Cuman RKN; Silva-Comar FMS; Comar JF; Brasileiro LDA; Santos JND; Oesterreich SA
    Molecules; 2020 Sep; 25(18):. PubMed ID: 32906733
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery of putative inhibitors against main drivers of SARS-CoV-2 infection: Insight from quantum mechanical evaluation and molecular modeling.
    Balogun TA; Chukwudozie OS; Ogbodo UC; Junaid IO; Sunday OA; Ige OM; Aborode AT; Akintayo AD; Oluwarotimi EA; Oluwafemi IO; Saibu OA; Chuckwuemaka P; Omoboyowa DA; Alausa AO; Atasie NH; Ilesanmi A; Dairo G; Tiamiyu ZA; Batiha GE; Alkhuriji AF; Al-Megrin WAI; De Waard M; Sabatier JM
    Front Chem; 2022; 10():964446. PubMed ID: 36304744
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    J Biomol Struct Dyn; 2023; 41(13):5915-5945. PubMed ID: 35848354
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Butein as a potential binder of human ACE2 receptor for interfering with SARS-CoV-2 entry: a computer-aided analysis.
    Kapoor N; Ghorai SM; Khuswaha PK; Bandichhor R; Brogi S
    J Mol Model; 2022 Aug; 28(9):270. PubMed ID: 36001177
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In silico approach for identifying natural lead molecules against SARS-COV-2.
    Gupta SS; Kumar A; Shankar R; Sharma U
    J Mol Graph Model; 2021 Jul; 106():107916. PubMed ID: 33892297
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Discovery of a Putative Allosteric Site in the SARS-CoV-2 Spike Protein Using an Integrated Structural/Dynamic Approach.
    Di Paola L; Hadi-Alijanvand H; Song X; Hu G; Giuliani A
    J Proteome Res; 2020 Nov; 19(11):4576-4586. PubMed ID: 32551648
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Computational Repurposing of Drugs and Natural Products Against SARS-CoV-2 Main Protease (M
    Piplani S; Singh P; Petrovsky N; Winkler DA
    Front Mol Biosci; 2022; 9():781039. PubMed ID: 35359601
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An Update on Promising Agents against COVID-19: Secondary Metabolites and Mechanistic Aspects.
    Jamshidnia M; Sewell RDE; Rafieian-Kopaei M
    Curr Pharm Des; 2022; 28(29):2415-2425. PubMed ID: 35899955
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular binding studies of anthocyanins with multiple antiviral activities against SARS-CoV-2.
    Akinnusi PA; Olubode SO; Salaudeen WA
    Bull Natl Res Cent; 2022; 46(1):102. PubMed ID: 35431537
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Druggability for COVID-19: in silico discovery of potential drug compounds against nucleocapsid (N) protein of SARS-CoV-2.
    Ray M; Sarkar S; Rath SN
    Genomics Inform; 2020 Dec; 18(4):e43. PubMed ID: 33412759
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Computational Approach to Combat COVID-19 Infection: Emerging Tools for Accelerating Drug Research.
    Sahoo BM; Bhattamisra SK; Das S; Tiwari A; Tiwari V; Kumar M; Singh S
    Curr Drug Discov Technol; 2022; 19(3):e170122200314. PubMed ID: 35040405
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Promising terpenes as SARS-CoV-2 spike receptor-binding domain (RBD) attachment inhibitors to the human ACE2 receptor: Integrated computational approach.
    Muhseen ZT; Hameed AR; Al-Hasani HMH; Tahir Ul Qamar M; Li G
    J Mol Liq; 2020 Dec; 320():114493. PubMed ID: 33041407
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug repurposing for identification of potential spike inhibitors for SARS-CoV-2 using molecular docking and molecular dynamics simulations.
    Lazniewski M; Dermawan D; Hidayat S; Muchtaridi M; Dawson WK; Plewczynski D
    Methods; 2022 Jul; 203():498-510. PubMed ID: 35167916
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
    Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
    J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A review of natural products, their effects on SARS-CoV-2 and their utility as lead compounds in the discovery of drugs for the treatment of COVID-19.
    Chapman RL; Andurkar SV
    Med Chem Res; 2022; 31(1):40-51. PubMed ID: 34873386
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapeutic Targets and Computational Approaches on Drug Development for COVID-19.
    Shanmugam A; Muralidharan N; Velmurugan D; Gromiha MM
    Curr Top Med Chem; 2020; 20(24):2210-2220. PubMed ID: 32648845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.